Loading
A phase 2 trial of Resminostat and Sorafenib in Hepatocellular carcinoma, run by 4SC AG, completed.
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma is a phase 2 interventional study registered as NCT00943449 by 4SC AG, with 57 participants recorded, started 2009-07 and reaching its primary completion in 2012-06. Interventions recorded: 4SC-201, Sorafenib. Conditions recorded: Hepatocellular Carcinoma.
Linked to the drug Resminostat because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.
Shares 4SC, Resminostat and the tag pipeline.
Shares 4SC, Resminostat and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tag pipeline.